Table 1.
Patient Characteristics
| UPN | AGE/SEX | DIAGNOSIS | DISEASE STATUS AT TIME OF MOBILIZATION | PRIOR CHEMOTHERAY (Regimens) | CHEMOTHERAPY TO D1 G-CSF (Days) | PRIOR LENALIDOMIDE THERAPY (Months) |
|---|---|---|---|---|---|---|
| 1 | 69/M | NHL | PR | RCHOP, RESHAP | 47 | - |
| 2 | 51/M | MM | CR | DVD, VM | 88 | - |
| 3 | 45/F | NHL | PR | R-CHOP, GCD, RICE | 47 | - |
| 4 | 39/F | HD | PR | ABVD, ICE, GVD | 61 | - |
| 5 | 57/M | NHL | CR | RCHOP, mBEAM | 44 | - |
| 6 | 59/M | MM | PR | VD, MPV, RD | 27 | 5 |
| 7 | 63/F | NHL | CR | RCHOP, RICE | 65 | - |
| 8 | 65/M | NHL | PR | RCHOP, RICE | 28 | - |
| 9 | 68/M | MM | CR | RD | 30 | 4 |
| 10 | 69/F | NHL | PR | RGO, RICE | 34 | - |
| 11 | 43/M | NHL | CR | RCHOP, RICE | 35 | - |
| 12 | 70/M | MM | PR | RD | 34 | 5 |
| 13 | 59/M | NHL | CR | RCHOP, RICE | 40 | - |
| 14 | 66/F | MM | PR | VDC | 27 | - |
| 15 | 60/M | HD | CR | ABVD, ICE | 38 | - |
| 16 | 67/M | MM | PR | MPV, RD | 22 | 15 |
| 17 | 68/M | NHL | CR | RCHOP, RESHAP | 69 | - |
| 18 | 60/M | MM | PR | RD | 14 | 4 |
| 19 | 56/M | MM | PR | RD | 21 | 12 |
| 20 | 67/M | NHL | CR | RCHOP, RICE | 49 | - |
NHL; Non-Hodgkin Lymphoma, HD; Hodgkin Lymphoma, MM; Multiple Myeloma RCHOP; rituximab, cyclosphosphamide doxorubicin prednisone, RESHAP; rituximab etoposide solumedrol cytarabine cisplatin, DVD; liposomal doxorubicin vincristine dexamethasone, VM; bortezomib melphalan, GCD; gemcitabine cisplatin dexamethasone, RICE; rituximab ifosphamide etoposide, ABVD; adriamycin vinblastine bleomycin vincristine dacarbazine, GVD; gemcitabine vinorelbine liposomal doxorubicin, mBEAM; mini carmustine etoposide cytarabine melphalan, VD; bortezomib dexamethasone, MPV; melphalan prednisone bortezomib, RD; lenolidomide dexamethasone, RGO; rituximab gemcitabine oxaliplatin, VDC; bortezomib dexamethasone cyclophosphamide